Rizatriptan

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Rizatriptan
Rizatriptan.svg
Systematic (IUPAC) name
N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Clinical data
Trade names Maxalt
AHFS/Drugs.com monograph
MedlinePlus a601109
Pregnancy
category
Legal status
  • ℞ (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 45%
Protein binding 14%
Metabolism by monoamine oxidase
Biological half-life 2–3 hours
Excretion 82% urine; 12% faeces
Identifiers
CAS Number 145202-66-0 YesY
ATC code N02CC04 (WHO)
PubChem CID: 5078
IUPHAR/BPS 51
DrugBank DB00953 YesY
ChemSpider 4900 YesY
UNII WR978S7QHH YesY
KEGG D00675 N
ChEBI CHEBI:48273 YesY
ChEMBL CHEMBL905 YesY
Chemical data
Formula C15H19N5
Molecular mass 269.345 g/mol
  • n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C
  • InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 YesY
  • Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N YesY
 NYesY (what is this?)  (verify)

Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches.[1] It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), France, Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt).

Indications

Rizatriptan is FDA-approved to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks.[1] Rizatriptan is also used off-label to treat cluster headaches.

Contraindications

Adverse effects

Mechanism of action

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors.[2] Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.[2]

References

  1. 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
  2. 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.

External links